lumbar radiculopathy
Recently Published Documents





2021 ◽  
Vol 4 (1) ◽  
pp. 119-124
Andrew Phillips ◽  
Anita Wong ◽  
Grace Chen ◽  
Jacob LaSalle ◽  
Jonathann Kuo

This One month safety study addresses any potential risks behind the use of bone marrow-derived mesenchymal stem cell extracellular vesicle isolate product (ExoFlo Direct Biologics) as a treatment for cervical and lumbar radiculopathy. Ten healthy adults were treated with ExoFlo injections for cervical radiculopathy (n=5) and lumbar radiculopathy (n=5). Follow up occurred twenty-four hours, three days, one week, three weeks and one month post injection. By the one month follow-up, the average patient improved 55% in BPI, 55.2% in QD, 25.4% in UEFS, 19.75% in ODI and 26% in LEFS. There were no complications or adverse events by the end of the study and no patient exhibited worsening radiculopathy. Patients will continue to be followed for at least six months post injection.

Cureus ◽  
2021 ◽  
Soubrata V Raikar ◽  
Arun A Patil ◽  
Deepak K Pandey ◽  
Sidharta R Kumar

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Leidy Plaza-Enriquez ◽  
P. Khatiwada ◽  
M. Sanchez-Valenzuela ◽  
A. Sikha

Background. Subacute thyroiditis has been reported after administration of influenza vaccine. We describe a case of a patient who developed subacute thyroiditis after administration of. Moderna mRNA COVID-19 vaccine. Case Presentation. A 42-year-old female, with a past medical history of stage IIIB pT3N1aM0 right adenocarcinoma of colon status, after right hemicolectomy on 01/2020, followed by adjuvant chemotherapy, paroxysmal supraventricular tachycardia, iron deficiency anemia, chemotherapy-induced neuropathy, and lumbar radiculopathy, presented to our clinic with anterior neck pain that started 6 days after the second dose of Moderna mRNA COVID-19 vaccine. She was diagnosed with subacute thyroiditis and treated conservatively with pain medications. Conclusion. Subacute thyroiditis could represent one of the side effects of Moderna mRNA COVID-19 vaccine. Further reports are lacking.

2021 ◽  
Vol 31 (4) ◽  
pp. 203-210
Jeonghun Han ◽  
Byunghak Park ◽  
Jaemin Son ◽  
Namwoo Lee ◽  
Dohyeon Kang ◽  

Pain Practice ◽  
2021 ◽  
Vivek Mehta ◽  
Kavita Poply ◽  
Alia Ahmad ◽  
Joanne Lascelles ◽  
Amin Elyas ◽  

2021 ◽  
Vol 12 ◽  
pp. 522
Lisa B.E. Shields ◽  
Vasudeva Iyer ◽  
Rukmaiah C. Bhupalam ◽  
Yi Ping Zhang ◽  
Christopher B. Shields

Background: Pseudotumor of the tensor fascia lata (TFL) consists of a rare, benign soft tissue mass/hypertrophy of the TFL that appears on the anterolateral aspect of the proximal thigh. Notably, this condition often mimics a malignant tumor and may be misdiagnosed as a sarcoma. Case Description: A 45-year-old male presented with left hip/groin pain, swelling, and a painful mass on the anterolateral aspect of the left hip/thigh. The symptoms had started 3 months ago following an L1-S1 lumbar laminectomy/fusion. The initial diagnosis was hip disease, and the patient underwent a left MR arthrogram. When this study demonstrated a tear of the left anterosuperior acetabular labrum plus an increased alpha angle causing femoroacetabular impingement, the patient then underwent a left hip arthroscopy. However, as he continued to complain of the hip mass, he was referred to an orthopedic oncologist whose presumptive diagnosis favored a sarcoma. Nevertheless, the pelvic MRI scan and ultrasound (US) confirmed the diagnosis of hypertrophy of the left TFL (US left 33.4 mm vs. right 14.4 mm). The patient was first treated with 50 units of locally injected botulinum. As there was no symptomatic relief, the plan was to repeat the injection within the next few months. Conclusion: Hypertrophy of TFL may mimic a neoplasm such as a sarcoma and contributes to what appears to be a lumbar radiculopathy. However, MR and US imaging should readily identify TFL and rule out malignant lesions such as sarcomas.

Sign in / Sign up

Export Citation Format

Share Document